Loading quotes...

Forecast

There is no analyst data available for this company.

News Go to news feed

Basilea partner Asahi Kasei starts phase 2 study of Cresemba in children in Japan

Asahi Kasei Therapeutics has started a multicenter, open‑label phase 2 study in Japan of Cresemba (isavuconazole) in children at risk for invasive mycoses to evaluate safety and pharmacokinetics. Cresemba is already approved for pediatric patients in the US, Canada, Europe and China, but in Japan it is so far approved only for adults. Worldwide in‑market sales of Cresemba amounted to USD 782 million in the April 2025–March 2026 period. » More on finanzen.net
Asahi Kasei secures license for Noguchi ADC technology

Asahi Kasei Life Science has acquired licensing rights for an ADC technology developed by the Noguchi Institute that enables control of drug–antibody ratio and binding sites and the conjugation of two different drugs to a single antibody. The partners plan joint research, commercialization and possible sublicensing to biopharma companies and CDMOs such as Bionova Scientific. Asahi Kasei will thereby strengthen its healthcare offering; InvestingPro rates the company as financially very strong and sees upside potential for the share price. » More on de.investing.com
Asahi Kasei acquires Aicuris for €780 million

Asahi Kasei has signed a definitive agreement to acquire all shares of Aicuris Anti-infective Cures for around €780 million; closing is expected in the first quarter of fiscal 2026. The acquisition expands Asahi Kasei’s specialty pharma portfolio with three assets, including the already licensed Prevymis, Pritelivir — which is nearing FDA approval with a 2026 target — and AIC468, currently in Phase I with a planned launch in 2030. Asahi Kasei expects the transaction to contribute positively to operating income from fiscal 2028 after amortization, strengthening its position in transplantation, nephrology and severe infectious diseases. » More on de.investing.com

Historical dividends Dividends

All dividend metrics All metrics

In 2026, Asahi Kasei has already paid €0.12 in dividends. The last payout was in June.

Financials

In the last quarter, Asahi Kasei had revenue of €4.45bn and net profit of €289.66m

(EUR)	June 2026	YoY
Revenue	4.45bn	2.18%
Gross profit	1.56bn	10.25%
Net profit	289.66m	149.03%
EBITDA	721.2m	61.17%

Fundamentals

Metric	Value
Market capitalization	€12.36bn
Number of shares	1.35bn
52-week high/low	€10.84 - €6.58
Dividend yield	2.52%
Dividends TTM	€0.23
Beta	0.66
P/E ratio	11.36
PEG ratio	0.18
P/B ratio	1.03
P/S ratio	0.69

Company profile

Asahi Kasei Corporation manufactures, processes, and sells chemical products in Japan and internationally. The company operates through three segments: Material, Homes, and Health Care. It provides caustic soda, chemical fertilizers, nitric acid, ammonia, acrylonitrile, methyl methacrylate, styrene, adipic acid, hexamethylene diamine, AH salt, propionitrile, sodium cyanide, acetonitrile, methacrylonitrile, cyclohexyl methacrylate, cyclohexanol, cyclohexane, and cyclohexene; polymers; chemical intermediates; additives; membranes and systems; clads and anchors; optical and printing materials; electronic materials; and lithium-ion battery and lead-acid battery separators. The company offers cupro fiber, lining fabric, stretch fiber, spunbond nonwovens, cupro nonwoven fabric, microfiber suede, oil-water separator, multifunctional nonwoven, deodorizing nonwoven, heat-press formable thermoplastic nonwoven, noise suppression sheet, nylon filaments, flame-resistant fiber, honeycomb fabric, cellulose nanobead, ecorise, biocradle, and bemliese products, as well as polymers; synthetic rubber; elastomers; kitchen and household products; cleaners; and packaging products. In addition, the company provides electronic devices; and autoclaved aerated concrete, foundation systems, insulation materials, and structural systems and components. Further, it involved in the construction of homes and apartments; management of rental units and condominiums; brokerage of used homes; remodeling; and mortgage financing, asset management services, and insurance products. Additionally, the company provides pharmaceuticals and diagnostic reagents; dialyzers; therapeutic apheresis; biotherapeutics and plasma derivative filters and equipment, and virus removal filters; leukocyte reduction filters; defibrillators, temperature management systems, and data solutions; and UVC LED products. Asahi Kasei Corporation was founded in 1922 and is headquartered in Tokyo, Japan.